Big-deal Gilead rheumatoid arthritis drug rejected by FDA

Filgotinib was the early centerpiece of Gilead's $5.1 billion expanded collaboration with Belgium's Galapagos NV.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.